Skip to main content
. 2018 Dec 19;30(2):250–258. doi: 10.1093/annonc/mdy540

Figure 1.

Figure 1.

Kaplan–Meier curves for (A) overall survival and (B) progression-free survival (central assessment) (FAS population) CapeOX, capecitabine plus oxaliplatin; FAS, full analysis set; SOX, S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin.